Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic

Li, Yan Xi; Shi, Zhifeng; Aibaidula, Abudumijiti; Chen, Hong; Tang, Qisheng; Li, Kay Ka Wai; Chung, Nellie Yuk Fei; Chan, Danny Tat Ming; Poon, Wai Sang; Mao, Ying; Wu, Jinsong; Zhou, Lei; Chan, Aden Ka Yin; Ng, Ho Keung

doi:10.18632/oncotarget.11378

Cited by 22 publications

(18 citation statements)

References 56 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned in Fuller, G N's study [46], 6 thorny cases of 1p/19q FISH-positive and IDH wild-type did not meet the diagnostic criteria for "oligodendroglioma, IDH mutations, and 1p/19q codeletion." Ho-Keung Ng et, al [50] also found 5 in 185 cases(2.7 %) presented as "IDH wildtype and 1p/19q codeletion" and did not warrant a diagnosis of "oligodendroglioma, IDH mutant and 1p/19q co-deleted." Our results also confirmed the presence of 1p/19q co-deleted and IDH wildtype oligodendrogliomas as described in the above studies.…”

Section: Discussionmentioning

confidence: 98%

Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center

Hu¹,

Wang²,

Xi³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background:The latest WHO classification of CNS tumors using the integrated phenotypic and molecular parameters (IDH, ATRX, 1p19q, TERT etc.) have reestablished the CNS tumors classification in addition to traditional histology. The establishment of glioma molecular typing can more accurately predict prognosis, better guide individualized treatment to improve survival. Methods: The expression of IDH1, ATRX, PHH3, P53 and Ki67 was detected by IHC. Molecular status of IDH1/2 and TERT were analyzed using Sanger sequencing. MGMT was explored using methylation-specific PCR. 1p/19q codeletion status was firstly detected by FISH, then further confirmed by multiplex PCR-based next generation sequencing. Results: The mutation frequency of IDH1 was 68.7% (79/115) in WHO II astrocytoma, and 82 cases (82/344, 23.8%) were "triple-negative glioma" in our cohort. Multivariate COX analysis revealed that only IDH, 1p/19q, TERT and MGMT were independent prognostic factors. Noteworthily, we found 7 cases of the new molecular phenotype presented as "IDH wildtype and 1p/19q codeletion", not mentioned in the latest WHO guideline. Conclusion: We detected the newly recommended markers in a large cohort of Chinese glioma patients. Our data demonstrated a relatively lower frequency of IDH mutations and a higher prevalence of triple-negative glioma in Chinese compared with American and European, indicating ethnic and geographical difference in some markers. In addition, the new molecular phenotype "IDH wildtype and 1p/19q codeletion" glioma deserved special focus. These findings suggest that further stratification of infiltrating gliomas is needed for different treatment strategy and precision medicine.

show abstract

Section: Discussionmentioning

confidence: 98%

Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center

Hu¹,

Wang²,

Xi³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Among them, anatomic location plays a crucial role not only for prognosis prediction but also for treatment strategy. It was widely acknowledged that prognosis is poor in midline glioma than non-midline tumor [ 10 ]. Regarding to hemispheric glioma, patient with tumor located in frontal lobe tends to be younger, IDH1 mutation and longer survival time [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

“…The status of 1p19q was determined by FISH (fluorescence in situ hybridization). A case of 50% tumor cells present with reference probe signal ratio to target probe signal more than 2:1 was considered 1p19q codeletion, otherwise we called 1p19q intact [ 10 ]. Molecular information will be integrated into regular pathological diagnosis.…”

Section: Methodsmentioning

confidence: 99%

Anatomic mapping of molecular subtypes in diffuse glioma

Tang

Lian

et al. 2017

BMC Neurol

Self Cite

View full text Add to dashboard Cite

BackgroundTumor location served as an important prognostic factor in glioma patients was considered to postulate molecular features according to cell origin theory. However, anatomic distribution of unique molecular subtypes was not widely investigated. The relationship between molecular phenotype and histological subgroup were also vague based on tumor location. Our group focuses on the study of glioma anatomic location of distinctive molecular subgroups and histology subtypes, and explores the possibility of their consistency based on clinical background.MethodsWe retrospectively reviewed 143 cases with both molecular information (IDH1/TERT/1p19q) and MRI images diagnosed as cerebral diffuse gliomas. The anatomic distribution was analyzed between distinctive molecular subgroups and its relationship with histological subtypes. The influence of tumor location, molecular stratification and histology diagnosis on survival outcome was investigated as well.ResultsAnatomic locations of cerebral diffuse glioma indicate varied clinical outcome. Based on that, it can be stratified into five principal molecular subgroups according to IDH1/TERT/1p19q status. Triple-positive (IDH1 and TERT mutation with 1p19q codeletion) glioma tended to be oligodendroglioma present with much better clinical outcome compared to TERT mutation only group who is glioblastoma inclined (median overall survival 39 months VS 18 months). Five molecular subgroups were demonstrated with distinctive locational distribution. This kind of anatomic feature is consistent with its corresponding histological subtypes.DiscussionEach molecular subgroup in glioma has unique anatomic location which indicates distinctive clinical outcome. Molecular diagnosis can be served as perfect complementary tool for the precise diagnosis. Integration of histomolecular diagnosis will be much more helpful in routine clinical practice in the future.

show abstract

“…In our study, the survival rate was higher in cases with IDH mutation, but no statistical difference was there (p=0.147). The presence of 1p/19q loss has been associated with long overall survival in patients regardless of treatment (21). In our study, the survival rate was 64.3% in cases without 1p/19q loss and 81.6% in cases with 1p/19q loss (p=0.178).…”

Section: Discussionmentioning

confidence: 45%

“…In a study conducted in 987 cases, median survival time was 11.6 years in oligodendrogliomas and 5.6 years in low-grade As. These values are similar for grade III tumors; a study conducted by the European Cancer Treatment and Research Organization-Brain Tumor Group, which included 368 patients, demonstrated that median survival time was 34.7 months in anaplastic oligodendrogliomas (21). IDH mutant tumors have better prognosis regardless of grade (12,22).…”

Section: Discussionmentioning

confidence: 71%

The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and The Role of PDGFRA Amplification as a Marker of Recurrence and Prognosis

Terzi¹,

Yılmaz²,

Öz³

2018

Balkan Med J

View full text Add to dashboard Cite

Background: With the help of genetic studies, it is possible to obtain information about diagnosis and prognosis of glial tumors. Aims: To categorize the cases according to the new World Health Organization Central Nervous System classification by reconsidering the histologic features of oligodendrogliomas, astrocytomas and oligoastrocytomas. We also evaluated whether these genetic features have prognostic significance. Study Design: Diagnostic accuracy study. Methods: Between the years 2011 and 2016, 60 gliomas were examined. Archival material from the Department of Pathology was used for histopathological, immunohistochemical, and molecular analyses. All the cases were classified and graded according to the new 2016 World Health Organization criteria. IDH1 (R132H), alpha thalassemia/mental retardation syndrome, and p53 antibodies were applied immunohistochemically. The 1p/19q status and plateletderived growth factor receptor-α/CEP4 amplification were evaluated by fluorescence in situ hybridization. After molecular tests, if the diagnosis of oligodendroglioma or astrocytoma is not diagnosed, case should be diagnosed as oligoastrocytoma. Sensitivity, specificity, positive predictive level, negative predictive level, and accuracy rate were evaluated in accordance with the specified threshold levels. Results: Except for 1 case (3.7%), all cases of grade 2 and grade 3 oligoastrocytoma were diagnosed with astrocytoma or oligodendroglioma without any change of grade. Except for 2 case (6.8%), all cases of grade 2 and grade 3 oligodendroglioma were diagnosed oligodendroglioma. All astrocytomas (100%) were given same diagnosis. There is no specific or sensitive test for the diagnosis of oligoastrocytoma. However, 1p/19q codeletion was spesific (100%) and sensitive (100%) for oligodendroglioma. ATRX and p53 mutation showed high spesificity (100% and 95.1% respectively) for diagnosing astrocytoma. Platelet-derived growth factor receptor-α/ CEP4 was not detected in any of the cases. There was association between isocitrate dehydrogenase mutation and 1p/19q loss with longer survival (respectively p=0.147 and p=0.178). Conclusion: In grade 2 and grade 3 glial tumors, pathological diagnosis is not possible only by histological examination. Overall, there was a diagnosis change in 28 cases (46.6%). Especially in cases of oligoastrocytoma, the diagnosis is changed by molecular tests.

show abstract

Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic

Cited by 22 publications

References 56 publications

Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center

Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center

Anatomic mapping of molecular subtypes in diffuse glioma

The Applicability of Haarlem Integrated Diagnostic System in Diffuse Glial Tumors and The Role of PDGFRA Amplification as a Marker of Recurrence and Prognosis

Contact Info

Product

Resources

About